Engineers Gate Manager’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.27M | Buy |
141,506
+28,452
| +25% | +$255K | 0.02% | 989 |
|
|
2025
Q1 | $848K | Buy |
113,054
+89,804
| +386% | +$674K | 0.01% | 1158 |
|
|
2024
Q4 | $175K | Sell |
23,250
-39,060
| -63% | -$294K | ﹤0.01% | 1909 |
|
|
2024
Q3 | $474K | Buy |
62,310
+33,330
| +115% | +$253K | 0.01% | 1401 |
|
|
2024
Q2 | $179K | Sell |
28,980
-12,300
| -30% | -$76K | ﹤0.01% | 1662 |
|
|
2024
Q1 | $210K | Sell |
41,280
-13,740
| -25% | -$69.8K | 0.01% | 1633 |
|
|
2023
Q4 | $330K | Sell |
55,020
-11,880
| -18% | -$71.2K | 0.01% | 1403 |
|
|
2023
Q3 | $474K | Buy |
66,900
+33,000
| +97% | +$234K | 0.02% | 1085 |
|
|
2023
Q2 | $239K | Sell |
33,900
-33,692
| -50% | -$237K | 0.01% | 1403 |
|
|
2023
Q1 | $564K | Buy |
+67,592
| New | +$564K | 0.02% | 917 |
|
|
2022
Q4 | – | Sell |
-54,467
| Closed | -$686K | – | 1679 |
|
|
2022
Q3 | $686K | Buy |
+54,467
| New | +$686K | 0.04% | 614 |
|
|
2021
Q3 | – | Sell |
-34,820
| Closed | -$551K | – | 1644 |
|
|
2021
Q2 | $551K | Buy |
+34,820
| New | +$551K | 0.04% | 777 |
|
|
2020
Q2 | – | Sell |
-10,000
| Closed | -$20K | – | 1690 |
|
|
2020
Q1 | $20K | Buy |
+10,000
| New | +$20K | ﹤0.01% | 1516 |
|